Celecoxib

For research use only.

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

41 publications

Celecoxib Chemical Structure

Molecular Weight(MW): 381.37

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 420 In stock
USD 70 In stock
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Celecoxib has been cited by 41 publications

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.
Targets
COX-2 [1]
(Sf9 cells)
40 nM
In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 NH7kVndHfW6ldHnvckBCe3OjeR?= MVewMlEuOzBizszN NEmy[WI1QCCq MmDibY5lfWOnczDJR2FONTFiZYjwdoV{e2mxbjDvckBjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yw> M1fXWVI3PTF|MUey
H460 Ml:ySpVv[3Srb36gRZN{[Xl? MoLNNE4yNTNyIN88US=> M1vHNlQ5KGh? MULpcoR2[2W|IFnDRW0uOSCneIDy[ZN{cW:wIH;uJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcC=> NIXBUWwzPjVzM{G3Ni=>
HKESC-2 NF;ZcmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\QNYhsOjEEoN88US=> NY[0VIdLPDkEoHlCpC=> NWnKZ4k6e2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgeIhmKEmFNUFCpJZidHWnczDv[kBwgGGuaYDsZZRqdsLi M{D6PFI3PDd2Nkmz
CaES-17 NXjnS2I3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWWyNOKh|ryP M{n0fFQ5yqCqwrC= M2[2d5Nq\26rZnnjZY51dHliaX7jdoVie2W|IITo[UBKSzVywrD2ZYx2\XNib3[gc5hidGmybHH0bY7DqA>? MnTINlY1PzR4OUO=
HKESC-2 NGjhPGdCeG:ydH;zbZMhSXO|YYm= Ml;wNlDDqM7:TR?= MYC0POKhcMLi M17BSpJm\HWlZYOgc5hidGmybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM> NXT4bI5HOjZ2N{S2PVM>
CaES-17 NEHOSWxCeG:ydH;zbZMhSXO|YYm= M3fRelIxyqEQvF2= NFnOSJk1QMLiaNMg MmDRdoVlfWOnczDvfIFtcXCuYYTpck1qdmS3Y3XkJIFxd3C2b4Ppdy=> NFf4dHIzPjR5NE[5Ny=>
A549 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[1MVE3OCEQvF2= NVrOdXNyPDkEoHlCpC=> M4jhVGROW09? MlXwTWM2OD1zNkOuOEDPxE1? Ml;TNlY1PjR4NEO=
HCC827 NUPH[4FPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rYeVUuOTZyIN88US=> MlnuOFjDqGkEoB?= MXnEUXNQ MXfJR|UxRTZ7LkKg{txO MlXONlY1PjR4NEO=
A549 NGLIe|hCeG:ydH;zbZMhSXO|YYm= MoLKPFAhyrWP NF7DXZA1QMLiaNMg Ml20SG1UVw>? MnvUbY5lfWOnczDhdI9xfG:|aYO= MVSyOlQ3PDZ2Mx?=
HCC827 M3TsdmFxd3C2b4Ppd{BCe3OjeR?= M324NVgxKML3TR?= M3zYUVQ5yqCqwrC= NVXFOJA2TE2VTx?= NGHobGNqdmS3Y3XzJIFxd3C2b4Ppdy=> NVvKW3lROjZ2NkS2OFM>
SGC-7901/DDP MkXzSpVv[3Srb36gRZN{[Xl? M2qz[lExyqEEtV2= NHvrNnAzPCCq M1LaRYlvcGmkaYTzJIN6[2yxb4j5[4Vv[XOnLUKgZY5lKFBvZ3z5Z49xem:2ZXnuJIV5eHKnc4Ppc44> MnjQNlY1ODd4NUO=
SGC-7901  NEHUc2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3YNlTDqGkEoB?= M1u5S2lEPTB;MUG1MlA5KM7:TR?= NGmwS3EzPjRyN{[1Ny=>
SGC-7901/DDP NEWzN|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLHNlTDqGkEoB?= Mn;PTWM2OD1|NT60OUDPxE1? MnTPNlY1ODd4NUO=
SGC-7901/DDP M2jySWFxd3C2b4Ppd{BCe3OjeR?= MUSxNOKhyrWP NVPuU3o3OjRiaB?= NF7HSGhqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIIfpeIgh[2m|cHzheIlv NFi0RYMzPjRyN{[1Ny=>
SGC-7901/DDP NXfifG0xTnWwY4Tpc44hSXO|YYm= Mmr1NVDDqML3TR?= NWTkb4lQOjRiaB?= NVTSNZd3cW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4YhWC2pbInjc5Bzd3SnaX6geIhzd3WpaDDicI9kc2mwZzDFVFItKGGwZDDpcoFkfGm4YYTpcochWEuDIHHu[EBEWkWEwrC= NWHPS2pkOjZ2MEe2OVM>
SGC-7901/DDP NIC3V2tHfW6ldHnvckBCe3OjeR?= MlT6NVDDqML3TR?= Mn7ENlQhcA>? NI\1WZVk[XW|ZYOgZUBu[XKtZXSg[IVkemWjc3WgbY4hfGinIHzleoVtKG:oIFLjcE0zKHC{b4TlbY4> MYiyOlQxPzZ3Mx?=
H357 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLKO{42NzFyIN88US=> NEXEUlQ1QCCq M1LQVGROW09? MXrpcohq[mm2czDj[YxtKGe{b4f0bOKh[2:vYnnu[YQhf2m2aDDTZYJ2fG:lbHH4 M2PNTVI3ODB7OEe0
TAF M3XJcmZ2dmO2aX;uJGF{e2G7 NVHZRXQxOTEEoNM1US=> NUD4NVRrPyCm NFf0fIZi\m[nY4TzJHRCTnNiYXTo[ZNqfmVicILvdIVzfGmncx?= M1zTO|I2QTh5MUK3
TAF M{XKTmZ2dmO2aX;uJGF{e2G7 NEHaU4EyOMLiwsXN NEHDcXY{OC1zMkCgcYlv NGTlbpRxd2:{bImgZYZn\WO2czDkRYt1KHCqb4PwbI9zgWyjdHnvckBkd26|ZYH1[Y51KHSxIFXHSkB{cWewYXzpcoc> MUOyOVk5PzF{Nx?=
TAF M{\5ZWZ2dmO2aX;uJGF{e2G7 MVqxNOKhyrWP MoLnOFghcA>? MoCybY5kemWjc3XzJGVITlJibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w NYDGeXRDOjV7OEexNlc>
PANC-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXqyNE83OC9zMECg{txO M{HGPVI1NzR6L{eyJIg> M2TyR4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NVviRWIzOjV7N{OwOlI>
PANC-1 NX3XbHNKTnWwY4Tpc44hSXO|YYm= NYDWPFI2OjBxNkCvNVAxKM7:TR?= NYPTWWpsOjRiaB?= MWnheJRmdnWjdIOgZ4VtdCCrbo\hd4lwdiCjbnSgcYloemG2aX;uJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXyxsA> M{jhOVI2QTd|ME[y
HeLa  NFvrOY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHiU5RkOjEEoN88UeKh NEHmNoszPMLiaB?= MmfS[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25? NH\NfVczPTd5MESyNy=>
SACC-83 NH\XOpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYOyNOKh|ryPwrC= NVeyUGtyOjUEoHi= MlHl[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25? NGize3EzPTd5MESyNy=>
HeLa  NILoc5BCeG:ydH;zbZMhSXO|YYm= NF64NYQzOMLizszNxsA> NUfJcGVNOjUEoHi= M3PETIVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBieG:ydH;zbZM> M4TzU|I2PzdyNEKz
SACC-83 MmruRZBweHSxc3nzJGF{e2G7 NELjZokzOMLizszNxsA> NXLNOGt{OjUEoHi= MnXz[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJIFxd3C2b4Ppdy=> MVuyOVc4ODR{Mx?=
HeLa  NV7RVIF6TnWwY4Tpc44hSXO|YYm= M{HHT|IxNzRyL{iwJO69VQ>? MnL2NlTDqGh? NF7hemJ2eHKnZ4XsZZR{KFCWRV6gdIFzfGmjbHz5JIJ6KGmwaHnibZRqdmdiU4CxMEBidmRiYXP0bZZifGW|IGDUSW4h[W6mIHnuZYN1cX[jdHXzJGFMXA>? NYH5e4xsOjV5N{C0NlM>
SACC-83 M13jWmZ2dmO2aX;uJGF{e2G7 MWmyNE81OC96MDFOwG0> NGDVcVAzPMLiaB?= NEi5bWp2eHKnZ4XsZZR{KFCWRV6gdIFzfGmjbHz5JIJ6KGmwaHnibZRqdmdiU4CxMEBidmRiYXP0bZZifGW|IGDUSW4h[W6mIHnuZYN1cX[jdHXzJGFMXA>? NVXGNpRnOjV5N{C0NlM>
HLCZ01 M3fr[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYew5qCUPjEEoNM1US=> Moj1OFghcA>? M1vqNWROW09? MoXCbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NV;uc2x1OjV5MkS4PVk>
HLCZ01 NVTHNFVxTnWwY4Tpc44hSXO|YYm= Ml;kOFDDqM7:TR?= MV[yOEBp NEDQd5lFVVOR NV;lRmN5cW6lcnXhd4V{KGGlY4XteYxifGmxbjDv[kBIOC:JMT3wbIF{\SClZXzsd{Bkd22kaX7l[EB4cXSqIFnGUk3PuQ>? MXSyOVczPDh7OR?=
HLCZ01 M{HZS2Fxd3C2b4Ppd{BCe3OjeR?= NWfnepFmPDEEoN88US=> MlXENlQhcA>? MUfEUXNQ NEK0TJpmdmijbnPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDJSm4u|rF? NYj2OYpSOjV5MkS4PVk>
HLCZ01 MnfhSpVv[3Srb36gRZN{[Xl? M1n4U|QxyqEQvF2= MUmyOEBp MYjEUXNQ M1\CXYlv[3KnYYPld{BVWkGLTDDlfJBz\XO|aX;uJINwdWKrbnXkJJdqfGhiSX70[ZJn\XKxbj5OtS=> NGC1cnIzPTd{NEi5PS=>
MGC803 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2eycFAuPjBizszN NYXRboJ{PzJiaB?= NHrYd2xKSzVyPUS3MlI26oDLwsJihKk3NjR|IN88US=> MX:yOVcxOTN5OB?=
SGC7901 M{PGRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPjbXUyOC14MDFOwG0> MoD2O|IhcA>? NUPCVnNKUUN3ME20N{42O+LCidMx5qCKPS5zMjFOwG0> M4fLeVI2PzBzM{e4
MGC803 NGjldlVHfW6ldHnvckBCe3OjeR?= MmTtOFDDqM7:TR?= M{fPSFgwOTZxMkSgbC=> M{PQPZVxemWpdXzheJMhS2KuLXKg[ZhxemW|c3nvci=> MVWyOVcxOTN5OB?=
SGC7901 MWnGeY5kfGmxbjDBd5NigQ>? MnnkOFDDqM7:TR?= M1XKdlgwOTZxMkSgbC=> M3\HOJVxemWpdXzheJMhS2KuLXKg[ZhxemW|c3nvci=> M4LLWlI2PzBzM{e4
MCF-7  M{C1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLYTI8yNzFyIN88US=> NFPXZoY4OiCq MV3EUXNQ NFnVdFNmdmijbnPld{Bk[WylaYTybY9tNWmwZIXj[YQh[2WubDDndo94fGhiaX7obYJqfGmxbh?= M4\IRVI2PjZ5NUGw
MDA-MB-231  NEXqbYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LJOlEwOTBizszN NV\VdINHPzJiaB?= NXzM[G4xTE2VTx?= NFvSTXdmdmijbnPld{Bk[WylaYTybY9tNWmwZIXj[YQh[2WubDDndo94fGhiaX7obYJqfGmxbh?= MV6yOVY3PzVzMB?=
MDA-MB-231 NXuwXVBFTnWwY4Tpc44hSXO|YYm= NVzLZ5hrOC12MDFCuW0> M2fTclQuOjRiaB?= NXjDTYRFcW6lcnXhd4V{KEORWD2yJJBzd3SnaX6g[ZhxemW|c3nvckBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MmPkNlU2QDd|Mkm=
MCF-7 Mn76SpVv[3Srb36gRZN{[Xl? Mmq2NE01OCEEtV2= NGf1T281NTJ2IHi= NHvyclVmdmijbnPld{B1cGViZX\m[YN1eyCxZjDUVGEhd25iQVLDS|Ih\XiycnXzd4lwdsLi MWOyOVU5PzN{OR?=
MCF7-MX  NHXNU5FHfW6ldHnvckBCe3OjeR?= NXHaTFdHOC12MDFCuW0> MWG0MVI1KGh? NIXZZVlmdmijbnPld{B1cGViZX\m[YN1eyCxZjDUVGEhd25iQVLDS|Ih\XiycnXzd4lwdsLi Ml62NlU2QDd|Mkm=
MDA-MB-231 NGf4[Y9HfW6ldHnvckBCe3OjeR?= M134WVAuPDBiwsXN MlPGOE0zPCCq NInuVW5{fGmvdXzheIV{KHSqZTDlfJBz\XO|aX;uJI9nKEGEQ1eyJJVxKHSxIESuNlchfGmvZYOgeI8h[2:wdILvcEBt\X[nbDDifUAyOiCqwrC= NIXWVJczPTV6N{OyPS=>
A2780 NF;ufmlHfW6ldHnvckBCe3OjeR?= NXH4TW96PS9zMD:xOUDPxE1? MVq0PEBp M1noRoRm[3KnYYPld{BEd3hvMjDlfJBz\XO|aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MVWyOVQzPDh7OB?=
SKOV3  MnrySpVv[3Srb36gRZN{[Xl? NWnBOVdjPS9zMD:xOUDPxE1? MYK0PEBp M{nSb4Rm[3KnYYPld{BEd3hvMjDlfJBz\XO|aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NU\6[FlxOjV2MkS4PVg>
A2780 MXPGeY5kfGmxbjDBd5NigQ>? NFHIcXk2NzFyL{G1JO69VQ>? M3HUeFQ5KGh? M3fPdYVt\X[jdHXzJJRp\SCneIDy[ZN{cW:wIH;mJGUu[2GmaHXybY4h[W6mIHvldoF1cW5? NV3ue|BiOjV2MkS4PVg>
SKOV3  NEL3WG9HfW6ldHnvckBCe3OjeR?= MmTYOU8yOC9zNTFOwG0> M2DMclQ5KGh? NIfCc|BmdGW4YYTld{B1cGViZYjwdoV{e2mxbjDv[kBGNWOjZHjldolvKGGwZDDr[ZJifGmw MnfLNlU1OjR6OUi=
A2780 NXHJR3BHTnWwY4Tpc44hSXO|YYm= MWm1M|ExNzF3IN88US=> MWO0PEBp NWDUVGt{\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKE5vY3HkbIVzcW5iYX7kJHZqdWWwdHnu NXvWSIdmOjV2MkS4PVg>
SKOV3  NIH4eYdHfW6ldHnvckBCe3OjeR?= M4G0SlUwOTBxMUWg{txO M1;pTlQ5KGh? MYfk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUk1k[WSqZYLpckBidmRiVnnt[Y51cW5? NVTUfYtyOjV2MkS4PVg>
A2780 NIXsZZJHfW6ldHnvckBCe3OjeR?= MlXDOU8yOC9zNTFOwG0> NFjKdWIyKGh? MV7pcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gdE1CU1RiYX7kJJAuTVKNIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MXqyOVQzPDh7OB?=
SKOV3  NIXCdY9HfW6ldHnvckBCe3OjeR?= NYD5fHBMPS9zMD:xOUDPxE1? NYf2PWhWOSCq NHy2fWhqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YheC2DS2SgZY5lKHBvRWLLJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M1jsOlI2PDJ2OEm4
HCT-15 MYfGeY5kfGmxbjDBd5NigQ>? NWfrOoNSOTBvNUCg{txO NVvQXXRHPi1|NjDo M1X4N4lv\HWlZYOgeIhmKGW6cILld5Nqd25ib3[gR29ZNTJiaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= MU[yOVIyQDB{OB?=
HT-29  NXvDTmFUTnWwY4Tpc44hSXO|YYm= MnvnNVAuPTBizszN NW\GSZFPPi1|NjDo MXLpcoR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFPPXE0zKGmwIHLveIgh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboSgcYFvdmW{ Mkf0NlUzOThyMki=
HSC3  MV7D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MlfXNQKBmzRyIN88US=> MmDpOFghcA>? NV;Cd41QUUN3ME2yOU42yrFzLke4NEDPxE1? NYPaZWFXOjVzOUi3PFk>
HSC3  NFLXfphCeG:ydH;zbZMhSXO|YYm= MoXVNlUh|ryP MnSyOFghcA>? MkjDbY5lfWOnczDhdI9xfG:|aYO= MorhNlUyQTh5OEm=
HSC3  NGTVOFVHfW6ldHnvckBCe3OjeR?= NIfCVnUzPSEQvF2= M3\3U|Q5KGh? NETSWGxmgGirYnn0d{B{cWewaX\pZ4FvfGy7IILl[JVk\WRibXnndoF1cW:wIHPvcYJqdmWmIIfpeIghS0WW NHvUWXIzPTF7OEe4PS=>
HSC3  M{\NfWZ2dmO2aX;uJGF{e2G7 M{fZ[|I2KM7:TR?= M3PIbVQ5KGh? NGfTTnVqdmirYnn0d{BJW0N|IHPlcIwhcW64YYPpc44h[2:vYnnu[YQhf2m2aDDDSXQ> NEHYN|kzPTF7OEe4PS=>
HSC3  MYnGeY5kfGmxbjDBd5NigQ>? MXWyOUDPxE1? NFz0N|M4OiCq NXrI[Zho\GWlcnXhd4V{KE2PUD2yJIFv\CCPTWCtPUBxem:2ZXnud:Kh MX2yOVE6QDd6OR?=
201T  NX3Fc21KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXIS4lCPzJiaB?= NX\hd|J[TE2VTx?= NIq5[m9KSzVyPUS4MlYhyrWP NILP[5kzPTB3N{m0NS=>
273T MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnTfmQ4OiCq NYjXPG52TE2VTx?= NEDsSm5KSzVyPUiwMlUhyrWP NFraZY0zPTB3N{m0NS=>
Hep-2 NXnhW|BuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\SN|AwPTBxMUCwJO69VQ>? NFzHbGQyOi9{ND:zOk81QCCq NID0eotFVVOR MU\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NHz6RpczPDl7OEW2OC=>
Hep-2 MYPBdI9xfG:|aYOgRZN{[Xl? NEXGPFY2OCEQvF2= MXywMVQ5KGh? M3rCVGROW09? NXmzNVBycW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> MViyOFk6QDV4NB?=
Hep-2 MUjGeY5kfGmxbjDBd5NigQ>? NI\tVYU2OCEQvF2= M1vGZlAuPDhiaB?= NYDBUpZTTE2VTx?= NFy5[5dz\WS3Y3XzJJRp\SC2ZXzvcYVz[XOnIHHjeIl3cXS7IHfyZYR2[WyueR?= NGi0[YQzPDl7OEW2OC=>
Hep-2 NXn6O4VXTnWwY4Tpc44hSXO|YYm= M2\VZ|UxKM7:TR?= M2HsblAuPDhiaB?= MkDJSG1UVw>? NFyzPXhl\WO{ZXHz[ZMhfGinIH3SUmEh\XiycnXzd4lwdiCxZjDoWGVTXA>? MWOyOFk6QDV4NB?=
SGC-7901 NWnISnliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWmxNE82OC9zMECg{txO MWiyOE81QC95MjDo NUXQfGJYTE2VTx?= MX7pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MojvNlQ6QTJ7NUi=
MKN-45 Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnVSmoyOC93MD:xNFAh|ryP Mo\oNlQwPDhxN{KgbC=> MUTEUXNQ NUTVWnlncW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= M2fJXlI1QTl{OUW4
SGC-7901 M2TyfmZ2dmO2aX;uJGF{e2G7 NULCUpJmOTBxNUCvNVAxKM7:TR?= NH7XVGQ1QCCq NEXFWYVFVVOR NYXneJI{\G:5boLl[5Vt[XSnczD0bIUhdVKQQTDlfJBz\XO|aX;uJIxmfmWuczDv[kBEV1hvMjDhcoQhWEOQQTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MkfNNlQ6QTJ7NUi=
MKN-45 M33PSWZ2dmO2aX;uJGF{e2G7 NXfjN4l[OTBxNUCvNVAxKM7:TR?= MkDmOFghcA>? MkTWSG1UVw>? MojS[I94dnKnZ4XsZZRmeyC2aHWgcXJPSSCneIDy[ZN{cW:wIHzleoVteyCxZjDDU3guOiCjbnSgVGNPSSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NF;xclczPDl7Mkm1PC=>
C666-1 Mo\3R5l1d3SxeHnjbZR6KEG|c3H5 MYGyNE05OCEQvF2= M{DOV|I1KGh? NYnkRXc6\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>? Mkn3NlQ5PTR6M{i=
CNE-1 NFW0fJVEgXSxdH;4bYNqfHliQYPzZZk> NYTNWm1wOjBvOECg{txO NIHnNZYzPCCq NGfz[|Nl\WO{ZXHz[ZMh[2:ub375JIZwem2jdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7lduKh NYfONlZuOjR6NUS4N|g>
CNE-2 NIj1TXlEgXSxdH;4bYNqfHliQYPzZZk> NF3YdFAzOC16MDFOwG0> NW\LOZN4OjRiaB?= NWLLNXN4\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>? MX:yOFg2PDh|OB?=
C666-1 MVjDfZRwfG:6aXPpeJkhSXO|YYm= Mn\SOlAh|ryP MWm3JIQ> MW\lcohidmOnczDyZYRq[XSrb36gZ5l1d3SxeHnjbZR6KHSqcn;1[4ghS0:[LUKt[IVx\W6mZX70JI1idm6nch?= M2fCfFI1QDV2OEO4
CNE-1 M13qTGN6fG:2b4jpZ4l1gSCDc4PhfS=> NUPQSI9mPjBizszN MoLZO{Bl NGHjWpNmdmijbnPld{Bz[WSrYYTpc44h[3m2b4TvfIlkcXS7IITodo92\2hiQ1;YMVIu\GWyZX7k[Y51KG2jbn7ldi=> M2LRfFI1QDV2OEO4
SNU-1041 M4HTN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvI[oYxNTRyIN88US=> Mln2OFghcA>? Mlj0bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NVO0VXE{OjR4OUK3NFM>
SNU-1041 Mo\iSpVv[3Srb36gRZN{[Xl? NXXlVVVDOjBxM{Cg{txO M1TVWFQhcA>? MXLpcoR2[2W|IHX4dJJme3Orb36gc4bDqEOKT2CsJGdTWDd6wrDhcoTDqFiEUEJCpIF1KHSqZTDSUmEhdGW4ZX|CpC=> Mni5NlQ3QTJ5MEO=
SNU-1041 M3ywVGZ2dmO2aX;uJGF{e2G7 NH;4[4ExNTRyIN88US=> Mny4OEBp NGHodW52eC2{ZXf1cIF1\XNiQ1jPVOKh[W[2ZYKgeJJm[XSvZX70JJdqfGhiaHnnbEBkd26lZX70doF1cW:wcx?= MmTtNlQ3QTJ5MEO=
SGC-7901 NFTJ[3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DlV|UxNTF{NTFOwG0> NH34dFgzPC92OD:3NkBp M2\YNIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NGq4Zm8zPDZ5NkO5OC=>
SGC-7901 NIrTSHpCeG:ydH;zbZMhSXO|YYm= NHjpTmUyODBizszN MnrPO|IhcA>? M1zmcIlv\HWlZYOgZZBweHSxc3nz M3fvd|I1Pjd4M{m0
SGC-7901 MX;GeY5kfGmxbjDBd5NigQ>? NF7yeGo4PS9zMECvNVI2KM7:TR?= M372OFI1NzR6L{eyJIg> M3z1Zolv[3KnYYPld{Bk[XOyYYPlMVgh[W6mID25JI1TVkFiZYjwdoV{e2mxbjDpckBjd3SqIITpcYUh[W6mIHTvd4UhdWGwbnXy MlPBNlQ3PzZ|OUS=
LMeC  M2OyTGZ2dmO2aX;uJGF{e2G7 MlP5NlAwPTBizszN M3\EN|Q5KGh? M332SIRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDwdo91\Wmw NIPDfmEzPDZ3Nke0Oi=>
CMeC-1 NIfjVlFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1ficFIxNzVyIN88US=> NU\M[4JXPDhiaB?= NXv3To9mcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MUeyOFY2Pjd2Nh?=
LMeC M4n2SGNmdGxiVnnhZoltcXS7IFHzd4F6 M1zLU|IxNzVyIN88US=> M4LZdlQ5KGh? M3HKS4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MV6yOFY2Pjd2Nh?=
CMeC-1 MV3GeY5kfGmxbjDBd5NigQ>? NEfMUnkzOC93MDFOwG0> M{S0SFQ5KGh? NUL3UmhYcW6mdXPld{BIOS2VIHHydoV{fA>? MY[yOFY2Pjd2Nh?=
LMeC MV3GeY5kfGmxbjDBd5NigQ>? MWOyNE82OCEQvF2= NYjUSZlbPDhiaB?= NXrnXY1zcW6mdXPld{BIOS2VIHHydoV{fA>? NUTyeZl4OjR4NU[3OFY>
CMeC-1 M3rPd2Z2dmO2aX;uJGF{e2G7 M{TC[|IxNzVyIN88US=> Mm\uOFghcA>? Mny1[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZiY4njcIlvKERzIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MlrhNlQ3PTZ5NE[=
LMeC M4PpbmZ2dmO2aX;uJGF{e2G7 NIfvO|IzOC93MDFOwG0> Mnn2OFghcA>? NETiN3ll\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDjfYNtcW5iREGgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M{[1XFI1PjV4N{S2
CMeC-1 NEPRbVZHfW6ldHnvckBCe3OjeR?= MV2yNE82OCEQvF2= NUj0dW9jPDhiaB?= MmjGbY5lfWOnczDjZZNx[XOnLUOgZYN1cX[jdHnvci=> M{D0dFI1PjV4N{S2
LMeC MnW3SpVv[3Srb36gRZN{[Xl? M170OFIxNzVyIN88US=> M{fITlQ5KGh? M2THSolv\HWlZYOgZ4F{eGG|ZT2zJIFkfGm4YYTpc44> NEPSVWEzPDZ3Nke0Oi=>
OVCAR-3 MV3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MX[xNEDDvU1? MXKxJIg> MWLlcohidmOnczDwZYNtcXSjeHXsMYlv\HWlZXSgc5ZiemmjbjDjZY5k\XJiY3XscEBl\WG2aNMg NXjjfmwxOjR3MkCyNlc>
OVCAR-3 NVv2PIRvSXCxcITvd4l{KEG|c3H5 MljHNVAhyrWP NYTIToR3OSCq MWHwdo9ud3SnczDwZYNtcXSjeHXsMYlv\HWlZXSgZZBweHSxc3nzxsA> MXiyOFUzODJ{Nx?=
OVCAR-3 MWjGeY5kfGmxbjDBd5NigQ>? MX6xNEDDvU1? NUXj[2k6OSCq MW\lcohidmOnczDwZYNtcXSjeHXsMYlv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmNToEoB?= MX6yOFUzODJ{Nx?=
OVCAR-3 MX3GeY5kfGmxbjDBd5NigQ>? M2nHblExKML3TR?= M17SV|EhcA>? NECwfXhld3ewLYLl[5Vt[XSnczDOSk3PwkJiYXP0bZZifGmxbjDpcoR2[2WmIHL5JJBi[2yrdHH4[Yw> MVqyOFUzODJ{Nx?=
OVCAR-3 MkTSSpVv[3Srb36gRZN{[Xl? NXK2ZoxzOTBiwsXN NGLyT2kyKGh? MofCbY5pcWKrdIOgdIFkdGm2YYjlcE1qdmS3Y3XkJGFsfCCyaH;zdIhwenmuYYTpc44> MWGyOFUzODJ{Nx?=
CF33 M{XkeGZ2dmO2aX;uJGF{e2G7 MWexNFAh|ryP MkLiNlQhcA>? NHXhOWxqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJGNQYC1{IIDyc5RmcW5iZYjwdoV{e2mxbh?= NILSZXozPDVyM{e4Ni=>
CF33 M4K0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHe5UmkyOC1zMECg{txO NU\QflhxOC12IHS= MVjpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NFzqPVAzPDVyM{e4Ni=>
CF33 M1rhdWZ2dmO2aX;uJGF{e2G7 Mly2NVAuOTByIN88US=> NW\ERYpzPC1{NDDo M4DJNoRm[3KnYYPld{Bk\WyuczDpckB1cGViUzDwbIF{\SCjbnSgbY5kemWjc3XzJINmdGy|IHnuJGcxN0dzIHHydoV{fA>? Mn\QNlQ2ODN5OEK=
LNCaP MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXf6[29FOi93L{GwJO69VQ>? MV[5OkBp MoHDbY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKGG2b4L2ZZN1[XSrbh?= NGnmU2gzPDJ7Nkm3PC=>
LNCaP NHXkSFFCeG:ydH;zbZMhSXO|YYm= NYXYUmZVOi93L{GwJO69VQ>? MUO5OkBp NEniclZqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=> NXjy[|A6OjR{OU[5O|g>
PC-3  MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[wMVUxKM7:TR?= M1T6b|Q56oDLaB?= MVjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MnjxNlQyOjd6OEK=
PC-3  Ml61R4VtdCCYaXHibYxqfHliQYPzZZk> NYjQNnNpOC1zMECg{txO MmTkO|IhcA>? MUjk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NXTVVZV1OjRzMke4PFI>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Fibronectin / Vimentin / N-cadherin / E-cadherin ; 

PubMed: 28978083     


(A) Celecoxib treatment reduces the mesenchymal phenotype in SUM149 cells.

COX-2; 

PubMed: 29515134     


L02 cells exposed to PA (200 μM) with different concentrations of celecoxib (Cel, 5-40 μM) for 24 h. Celecoxib decreased protein expression of COX-2 compared with control as indicated by western blot. 

pAKT / AKT / PPARγ / PTEN ; 

PubMed: 24721996     


Immunoblots from N1-S1 cells treated with different dose celecoxib for 48 h. 

28978083 29515134 24721996
Immunofluorescence
PPARγ / PTEN ; 

PubMed: 24721996     


Immunofluorescence analysis in N1-S1 cells treated with 10 μM celecoxib for 48 h.

24721996
Growth inhibition assay
Cell viability; 

PubMed: 28521485     


Celecoxib caused the concentration-dependent inhibition of (A) GBC-SD and (B) NOZ cell growth. 

28521485
In vivo Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]

Protocol

Kinase Assay:[1]
- Collapse

COX enzyme assay in vitro:

Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:[2]
- Collapse
  • Cell lines: HNE1 and CNE1-LMP1
  • Concentrations: 0-75 μM
  • Incubation Time: 48 hours
  • Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
  • Dosages: ≤200 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (199.28 mM)
Ethanol 33 mg/mL (86.53 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 381.37
Formula

C17H14F3N3O2S

CAS No. 169590-42-5
Storage powder
in solvent
Synonyms SC 58635
Smiles CC1=CC=C(C=C1)C2=CC(=N[N]2C3=CC=C(C=C3)[S](N)(=O)=O)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03896113 Recruiting Drug: Celecoxib 200mg capsule Endometrium Cancer Cliniques universitaires Saint-Luc- Université Catholique de Louvain November 13 2019 Phase 2
NCT03643744 Recruiting Drug: Celecoxib 200mg|Drug: Placebo Actinic Keratosis|Photodynamic Therapy Jeffrey B. Travers MD PhD|Wright State Physicians April 1 2019 Phase 1
NCT01344200 Not yet recruiting Drug: Celecoxib Pharmacokinetics of Celecoxib in Children Children''s Hospital of Eastern Ontario March 2019 Phase 4
NCT02876094 Recruiting Drug: celecoxib Spinal Muscular Atrophy (SMA) Hugh McMillan|Families of Spinal Muscular Atrophy|Gwendolyn Strong Foundation|Children''s Hospital of Eastern Ontario January 29 2019 Phase 2
NCT03672162 Recruiting Procedure: Total abdominal hysterectomy Total Abdominal Hysterectomy Pain Acute PostoperativeGabapentin Celecoxib Rajavithi Hospital September 1 2018 Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?

  • Answer:

    For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Related COX Products

Tags: buy Celecoxib | Celecoxib supplier | purchase Celecoxib | Celecoxib cost | Celecoxib manufacturer | order Celecoxib | Celecoxib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID